Rob Medcalf Is Working On a Novel Thrombolytic Drug
Monash Translational Medicine shared on LinkedIn:
”Time is brain’ when a person has a stroke.
But even when a patient receives medical attention within 60 minutes, that’s often not enough: tPA, the main drug currently used to treat acute ischemic stroke (the most common stroke type in Australia) isn’t effective for the majority of patients.
Professor Rob Medcalf, of the Australian Centre for Blood Diseases based at Monash Translational Medicine, is working on a novel thrombolytic (clot-busting) drug that could give many more stroke patients a better chance of recovery.
He’s been awarded two Monash University grants – from the Monash Research Impact Fund (MIRF) and the MNHS Commercialisation Incubator Program (MCIP) – to progress development of the drug.
”We desperately need more drug options to treat stroke, for the many patients who can’t go on TPA for reasons ranging from the other medications they’re on, to the short window for effective treatment,” Rob says.
‘These grants will help us address some of the challenges of bringing new drugs to market.”’
-
Jan 14, 2026, 16:22Leo Nicolai and Rainer Kaiser Link Procoagulant Platelets and Thromboinflammation in CVD
-
Jan 14, 2026, 16:01Renato Simonetti Presents a Pilot Project on AI-assisted Duplex Sonography for ICH
-
Jan 14, 2026, 15:47An Unusual Case from Mohammed Ameen: Unexpected Clot Unmasking Antithrombin III Deficiency
-
Jan 14, 2026, 11:38Khokon Miah Akanda Shares A major 4-Guideline Comparison on BP Management in Stroke
-
Jan 14, 2026, 11:26Pablo Albasanz-García and Colleagues on Anticancer Treatment-Induced Arterial and Venous Thrombosis
-
Jan 14, 2026, 11:16ISTH 2026: Laurent Bertoletti To Serve as Vice Theme Leader for VTE
-
Jan 14, 2026, 11:08Leni von Bonsdorff Invites You to Hear and Learn The Latest News in The Plasma Field
-
Jan 14, 2026, 05:56Arun V J on The “Whole Blood” Nostalgia Trap
-
Jan 13, 2026, 16:38Caitlin Raymond: Understanding TAMOF as a TTP-Like Process